Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins

Authors:

Abstract
The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7–11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associated toxicity. In addition to inhibiting the aggregation and transit of TDP-43 to stress granules, we find that the in vivo delivery of an ataxin-2-targeting Cas13 system to a mouse model of TDP-43 proteinopathy improved functional deficits, extended survival, and reduced the severity of neuropathological hallmarks. Further, we benchmark RNA-targeting CRISPR platforms against ataxin-2 and find that high-fidelity forms of Cas13 possess improved transcriptome-wide specificity compared to Cas7–11 and a first-generation effector. Our results demonstrate the potential of CRISPR technology for TDP-43 proteinopathies.
All Related Versions
Funding Information
  • U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1U01NS122102-01A1, 1R01NS123556-01A1)
  • U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5R01GM141296)
  • Muscular Dystrophy Association (MDA602798)
  • Simons Foundation (887187)
  • Parkinson’s Disease Foundation (PF-IMP-1950)
  • U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (T32EB019944)
  • The Judith & Jean Pape Adams Foundation